Translational Rational for the Clinical Development of OTX-008: A Novel Drug That Inhibits Galectin-1 Expression in Human Cancer Models

Clinical Development of Novel Drug–Radiotherapy Combinations

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-2466 ◽

2018 ◽

Vol 25 (5) ◽

pp. 1455-1461 ◽

Cited By ~ 10

Author(s):

Saif S. Ahmad ◽

Marka R. Crittenden ◽

Phuoc T. Tran ◽

Paul G. Kluetz ◽

Gideon M. Blumenthal ◽

...

Keyword(s):

Clinical Development ◽

Anti-VEGF Strategies – from Antibodies to Tyrosine Kinase Inhibitors: Background and Clinical Development in Human Cancer

Current Pharmaceutical Design ◽

10.2174/138161212800626166 ◽

2012 ◽

Vol 18 (19) ◽

pp. 2680-2701 ◽

Cited By ~ 15

Author(s):

Grzegorz Korpanty ◽

Elizabeth Smyth

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Kinase Inhibitors ◽

Human Cancer ◽

Clinical Development ◽

Anti Vegf

220 POSTER Combination of class I PI3K inhibitor, GDC-0941, with standard of care therapeutics results in enhanced anti-tumor responses in human cancer models in vitro and in vivo

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)72152-9 ◽

2008 ◽

Vol 6 (12) ◽

pp. 69-70 ◽

Cited By ~ 1

Author(s):

D. Sampath ◽

M. Belvin ◽

J. Guan ◽

K. Edgar ◽

J. Wallin ◽

...

Keyword(s):

Human Cancer ◽

Standard Of Care ◽

Pi3k Inhibitor ◽

Class I ◽

Advances in the approach to novel drug clinical development for breast cancer

Expert Opinion on Drug Discovery ◽

10.1517/17460441.2014.911282 ◽

2014 ◽

Vol 9 (6) ◽

pp. 647-668 ◽

Cited By ~ 5

Author(s):

Cristiano Ferrario ◽

Gerald Batist

Keyword(s):

Breast Cancer ◽

Clinical Development ◽

Bioinformatics Approaches to Integrate Cancer Models and Human Cancer Research

Cancer Bioinformatics ◽

10.1002/0470032898.ch9 ◽

2006 ◽

pp. 155-168

Author(s):

Cheryl L. Marks ◽

Sue Dubman

Keyword(s):

Cancer Research ◽

Human Cancer ◽

Abstract A194: OTX008, a small molecule that inhibits galectin-1, potentiates the in vitro effects of cytotoxic and targeted agents in several human cancer models.

10.1158/1535-7163.targ-13-a194 ◽

2013 ◽

Author(s):

Lucile Astorgues-xerri ◽

Maria Eugenia Riveiro ◽

Kay Noel ◽

Esteban Cvitkovic ◽

Mohamed Bekradda ◽

...

Keyword(s):

Small Molecule ◽

Human Cancer ◽

Targeted Agents ◽

Cancer Models ◽

In Vitro Effects

A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus

European Journal of Pharmaceutical Sciences ◽

10.1016/j.ejps.2019.05.020 ◽

2019 ◽

Vol 136 ◽

pp. 104942 ◽

Cited By ~ 2

Author(s):

Xueting Yao ◽

Yiwen Wu ◽

Ji Jiang ◽

Xia Chen ◽

Dongyang Liu ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Pharmacokinetic Study ◽

Lupus Erythematosus ◽

Early Phase ◽

Clinical Development ◽

Population Pharmacokinetic ◽

Systemic Lupus ◽

Population Pharmacokinetic Study ◽

Translating Human Cancer Sequences Into Personalized Porcine Cancer Models

Frontiers in Oncology ◽

10.3389/fonc.2019.00105 ◽

2019 ◽

Vol 9 ◽

Cited By ~ 2

Author(s):

Chunlong Xu ◽

Sen Wu ◽

Lawrence B. Schook ◽

Kyle M. Schachtschneider

Keyword(s):

Human Cancer ◽

1069 Mouse p53-deficient Cancer Models as Platforms to Obtain Genomic Predictors for Human Cancer Clinical Outcome

European Journal of Cancer ◽

10.1016/s0959-8049(12)71678-7 ◽

2012 ◽

Vol 48 ◽

pp. S258

Author(s):

M. Duenas ◽

M. Santos ◽

J.F. Aranda ◽

A.B. Martinez-Cruz ◽

C. Lorz ◽

...

Keyword(s):

Clinical Outcome ◽

Human Cancer ◽

AR36A36.11.1, a monoclonal antibody targeting CD59, enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models

Molecular Immunology ◽

10.1016/j.molimm.2007.06.094 ◽

2007 ◽

Vol 44 (16) ◽

pp. 3948-3949

Author(s):

Baldwin C. Mak ◽

Fortunata McConkey ◽

Ningping Feng ◽

Kevin O’Reilly ◽

Daniel Rubinstein ◽

...

Keyword(s):

Monoclonal Antibody ◽

Human Cancer ◽

In Vivo Efficacy ◽

Complement Activity ◽

Cancer Models ◽

Antibody Targeting